Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Using OFR Software to Observe the Effects of Inclisiran Combined with Statins on the Morphology and Vascular Function of Coronary Vulnerable Plaques

Next Previous
Trial Profile

Using OFR Software to Observe the Effects of Inclisiran Combined with Statins on the Morphology and Vascular Function of Coronary Vulnerable Plaques

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inclisiran (Primary) ; Rosuvastatin (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms EItoCVP

Most Recent Events

  • 14 Feb 2025 Planned End Date changed from 1 May 2025 to 31 Dec 2025.
  • 14 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 30 Jun 2025.
  • 14 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top